<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820972</url>
  </required_header>
  <id_info>
    <org_study_id>HX-A-007（2021）</org_study_id>
    <nct_id>NCT04820972</nct_id>
  </id_info>
  <brief_title>Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage</brief_title>
  <official_title>Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Xiangya Hospital of Central South Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangzhou Red Cross Hospital ，Jinan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Binzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Provincial People Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, prospective, open-label, endpoint-blind, randomized controlled&#xD;
      study.Patients receiving surgical treatment for SICH were divided into groups using the&#xD;
      random machine method. In addition to conventional treatment for spontaneous intracerebral&#xD;
      hemorrhage, patients in the group of early initiation of antiplatelet therapy were given&#xD;
      conventional dose of aspirin (100mg, qd) antiplatelet therapy starting from the 3rd day after&#xD;
      surgery.An independent group of investigators evaluated cardiac, cerebral and peripheral&#xD;
      vascular events and bleeding events at four different time points.To evaluate the benefits&#xD;
      and safety of early postoperative initiation of antiplatelet therapy in patients with&#xD;
      spontaneous intracerebral hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of intracranial hemorrhage</measure>
    <time_frame>7 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of intracranial hemorrhage</measure>
    <time_frame>14 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of intracranial hemorrhage</measure>
    <time_frame>30 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of intracranial hemorrhage</measure>
    <time_frame>90 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of major adverse cardiac/cerebrovascular and peripheral vessel events</measure>
    <time_frame>7 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of major adverse cardiac/cerebrovascular and peripheral vessel events</measure>
    <time_frame>14 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of major adverse cardiac/cerebrovascular and peripheral vessel events</measure>
    <time_frame>30 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of major adverse cardiac/cerebrovascular and peripheral vessel events</measure>
    <time_frame>90 days after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Spontaneous Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>E-STAR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>traditional group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet Agents</intervention_name>
    <description>using antiplatelet agents in 3 days after surgery</description>
    <arm_group_label>E-STAR group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old.&#xD;
&#xD;
          -  nontraumatic spontaneous intracerebral hemorrhage.&#xD;
&#xD;
          -  postoperative patients with high risk of MACCPE:(1)previous history of cerebral&#xD;
             infarction or TIA. (2)previous history of coronary heart disease or myocardial&#xD;
             infarction.(3) use ASCVD Risk Estimator&#xD;
             Plus（http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/） to assess&#xD;
             the risk of ischemic events for patients with no previous history of cerebral&#xD;
             infarction, TIA, or coronary heart diseases or myocardial infarction,10 years risk&gt;10%&#xD;
             is defined as a high risk of cardiovascular ischemic events(4)The Caprini Risk Scale&#xD;
             is used to assess the risk of venous thrombosis in the lower extremities.Score&gt;2 is&#xD;
             defined as a high risk of venous thrombosis.&#xD;
&#xD;
          -  patients who received neurosurgical procedures to remove the hematoma, including&#xD;
             craniotomy, endoscopic hematoma removal and hematoma aspiration.&#xD;
&#xD;
          -  patients who signed informed consent.&#xD;
&#xD;
          -  no history of allergy to salicylic acid preparation.&#xD;
&#xD;
          -  patients who complete the preintervention assessment and meet the fellow&#xD;
             criteria:(1)postoperative head CT showed no new infarction or&#xD;
             hemorrhage(2)postoperative venous ultrasound of the lower extremity did not reveal&#xD;
             deep vein thrombosis.(3)postoperative electrocardiogram and myocardial enzyme&#xD;
             examination did not show acute myocardial ischemia or myocardial infarction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  there are structural cerebrovascular lesions (such as intracranial aneurysms,&#xD;
             cerebrovascular malformations, etc.) or tumors in the area of bleeding or the bleeding&#xD;
             is suspected to be related to these lesions.&#xD;
&#xD;
          -  ischemic stroke with hemorrhagic conversion.&#xD;
&#xD;
          -  secondary bleeding due to venous embolism.&#xD;
&#xD;
          -  the malignant tumor is expected to have a survival of no more than 3 months.&#xD;
&#xD;
          -  take antithrombotic agents((Vitamin K antagonists (warfarin) new&#xD;
             anticoagulants(Dabigatun Rivaroxaban))) in addition to antiplatelet agents.&#xD;
&#xD;
          -  previous history of thrombocytopenia or coagulation disorders.&#xD;
&#xD;
          -  previous history of atrial fibrillation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuo Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JUN WU, MD</last_name>
    <phone>+8613426322945</phone>
    <email>wujunslf@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuo Wang, MD</last_name>
    <phone>13801180330</phone>
    <email>captain9858@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Capital Medical University Affiliated Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Wang Shuo</investigator_full_name>
    <investigator_title>Director of Department of Cerebrovascular Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>antiplatelet treatment</keyword>
  <keyword>spontaneous intracerebral hemorrhage</keyword>
  <keyword>early-start</keyword>
  <keyword>neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

